Kodiak Sciences Inc. (KOD) has a MoatMap StockRank of 37/100 based on Quality (25/100), Value (33/100), and Momentum (66/100) factor scores. The current signal is HOLD. Kodiak Sciences Inc. is a biotechnology company. There is no clear or direct thematic tailwind from the identified macro themes that would create an asymmetric opportunity for a biotech firm within an 18-month horizon.
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for common retinal diseases, such as wet AMD and diabetic macular edema. The company's competitive edge lies in its proprietary KSI technology platform, which aims to create long-acting intravitreal treatments to reduce patient injection burden. It operates as a focused biotech player, leveraging its specialized platform to address significant unmet medical needs in ophthalmology.
| Price | $36.12 |
| Market Cap | $2.3B |
| P/E (Forward) | -11.55 |
| Price/Book | 19.91 |
| Return on Equity | -208.8% |
| Return on Invested Capital | -75.2% |
| Debt/Equity | 49.95 |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
| Free Cash Flow | $-52M |
Kodiak Sciences Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).